Alcohol Pharmacotherapy for HIV+ Prisoners


AIDS | Alcohol Dependence | Hazardous Drinking | Human Immunodeficiency Virus | Problem Drinking

What is the purpose of this trial?

This is a randomized controlled trial of injectable intramuscular naltrexone (XR-NTX) versus intramuscular placebo among HIV-infected prisoners meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for alcohol dependence or problem drinking, who are transitioning to the community and seeking treatment to prevent relapse to alcohol use. We hypothesize that extended release naltrexone (XR-NTX) will result in improved HIV outcomes (lower log10 HIV-1RNA levels and higher CD4 count) as well as improved alcohol treatment outcomes, and reduced drug/sex HIV related risk behaviors and decreased rates of reincarceration.

Participation Guidelines

18 Years and older

Click here for detailed information about who can participate in this trial.

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Yale University
August 2010
Last Updated:
July 8, 2014
Study HIC#:
0908005572 ID: NCT01077310